Participants 220 278 3
patients with upper gastrointestinal adenocarcinoma (UGIA)
Participants 291 423 6
Seventy-three patients with advanced UGIA were randomised to receive 45 mg/m2 docetaxel or 180 mg/m2 irinotecan with 5-FU/leucovorin
Participants 1349 1394 4
patients with UGIA on palliative chemotherapy
